Descriptive only

Discontinuation due to adverse events

Type 2 diabetes (adults)

longest follow-upRecorded harmsEach dose separatelyHazard ratio (from event counts)Separate part 2 of a disconnected network

Randomized trials

Treatments

110

Participants

Events

In plain language

No network meta-analysis was fitted here. The protocol requires at least two trials forming a connected network; this outcome has 2 trials. The trial data below are shown as reported.

Network of trials

Each circle is a treatment; each line joins treatments that were randomized against each other in at least one trial.

Node area shows participants; line width shows trials comparing two treatments directly. Blue: GLP-1 receptor agonist containing treatments; grey: comparators. Hover over or tab to a node or line for details.

Baseline characteristics of the trials

The baseline value of each effect modifier or prognostic factor that applies here, per trial: mean or percent over arms, weighted by the number randomized. A note under a value names a stand in (a median for a mean, 100 minus the male share, Asian subgroup rows, an all Asian site list); "not reported" means no source of the trial prints it.

Baseline effect modifiers and prognostic factors per trial
Trial	Sex (percent female) effect modifier, prognostic factor; 2 of 2	Asian ancestry or region (percent Asian) effect modifier, prognostic factor; 0 of 2
LIRAVIS S000773	71.4	not reported
S003442 S003442	100	not reported

Comparability of the trials

Checked across designs (the set of treatments each trial compares) for eligibility, outcome definition and assessment, and the baseline factors above. Flags point to possible intransitivity; notes describe variation that is not tied to design.

FlagBaseline, Sex: design means range from 71.4 (LIRA_SC_1p2MG_QD vs VILDAGLIPTIN) to 100.0 (DULA_SC_FLEX_0p75-1p5_QW vs LIRA_SC_1p2MG_QD) percent female; threshold 15
FlagBaseline, Asian ancestry or region: not reported by 2 of 2 trials
FlagOutcome assessment, analysis set: confounded with design: other 1, randomized 1
FlagRisk of bias, blinding: confounded with design: not_reported 1, single_blind 1
FlagRisk of bias, funding: confounded with design: non_industry 1, not_reported 1
NoteOutcome assessment, time point: selected time points span 2 to 24 weeks
NoteData handling, input conversions: printed_denominator 2

Comparability items per trial
Trial	time weeks	analysis set	definition	instrument	adjudicated	proportion method	intercurrent events (discontinuation)	intercurrent events (rescue)	blinding	funding	start year	Eligibility
LIRAVIS	2	randomized	not stated	not stated	not stated	not stated	not stated	not stated	single_blind	not_reported	2016	adults with type 2 diabetes on one or two oral drugs; HbA1c 7 percent or more; eGFR 30 or more; incretin naive
S003442	24	other	not stated	not stated	not stated	not stated	not stated	not stated	not_reported	non_industry	2019	Women with T2D by ADA criteria; no weight loss drugs within 24 weeks

Trial data

What each trial contributes. Arm rows give the arm value with its standard error, or events over participants; contrast rows give the hazard ratio (from event counts) on the analysis scale (log) against the trial's first row. Flags mark converted, combined or approximated inputs.

Trial data entering this analysis
Trial	Arm	Treatment	Week	Data	Events / N	Flags	Source
LIRAVIS	A1	LIRA_SC_1p2MG_QD	2	arm, events	0 / 7		R0055449:Figure 1
LIRAVIS	A2	VILDAGLIPTIN	2	arm, events	0 / 7		R0055449:Figure 1
S003442	A1	DULA_SC_FLEX_0p75-1p5_QW	24	arm, events	0 / 48	printed_denominator	R0016372:Results
S003442	A2	LIRA_SC_1p2MG_QD	24	arm, events	0 / 48	printed_denominator	R0016372:Results

Rerun this analysis yourself

Remove treatments or trials and refit the frequentist and Bayesian models in your browser, with the same methods as the published analysis.

Open in the NMA lab